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Aims: We previously reported that recombinant human Secretory Leukocyte Protease Inhibitor (SLPI) inhibits
mitogen-induced proliferation of human peripheral blood mononuclear cells. To determine the relevance of
this effect in vivo, we investigated the immuno-regulatory role of SLPI in an experimental autoimmune
orchitis (EAO) model.
Main methods: In order to increase SLPI half life, poly-ε-caprolactone microspheres containing SLPI were
prepared and used for in vitro and in vivo experiments. Multifocal orchitis was induced in Sprague–Dawley
adult rats by active immunization with testis homogenate and adjuvants. Microspheres containing SLPI (SLPI
group) or vehicle (control group) were administered s.c. to rats during or after the immunization period.
Key findings: In vitro SLPI-release microspheres inhibited rat lymphocyte proliferation and retained trypsin
inhibitory activity. A significant decrease in EAO incidence was observed in the SLPI group (37.5%) versus the
control group (93%). Also, SLPI treatment significantly reduced severity of the disease (mean EAO score:
control, 6.33±0.81; SLPI, 2.72±1.05). In vivo delayed-type hypersensitivity and ex vivo proliferative
response to testicular antigens were reduced by SLPI treatment compared to control group (pb0.05).
Significance: Our results highlight the in vivo immunosuppressive effect of released SLPI from microspheres
which suggests its feasible therapeutic use.
© 2011 Elsevier Inc. All rights reserved.Introduction
Secretory leukocyte protease inhibitor (SLPI) is an 11.7 kDa
nonglycosylated protein originally identified in parotid gland secre-
tions and in cervical, nasal and bronchial mucous. SLPI has been
identified as a serine protease inhibitor with activity against cathepsin
G, trypsin, and chymotrypsin, but primarily against neutrophil
elastase (Saitoh et al., 2001). Expression of SLPI is induced in response
to diverse inflammatory stimuli in various types of cells such as
epithelial cells, neutrophils and alveolar macrophages (Saitoh et al.,
2001; van Wetering et al., 2000a, 2000b; Williams et al., 2006). In the
lung, SLPI is an alarm-mediating acute phase reactant secreted in
response to LPS (Jin et al., 1998), interleukin-1, TNF-α (Sallenave et
al., 1994), EGF (Velarde et al., 2005), defensins (van Wetering et al.,
2000a, 2000b) and neutrophil elastase (Sallenave et al., 1994; van
Wetering et al., 2000a, 2000b).cología, Piso 9, Facultad de
, C.P. 1121, Ciudad Autónoma
0.
yan).
l rights reserved.Strong evidence of widespread local production of SLPI in the male
reproductive tract was shown by the presence of SLPI observed in
seminal plasma from healthy volunteers (Ohlsson et al., 1995). SLPI
expression was detected in epithelial cells of prostate glands,
epididymis, seminal vesicles and the apical parts of germinal
epithelium of the testis (Franken et al., 1989). The most likely the
role of SLPI in themale and the female reproductive tract now appears
to be a local protective function during inflammatory processes
(Casslen et al., 1981; Wallner and Fritz, 1974).
SLPI has numerous functions unrelated to its protease-inhibitory
activity since it may also function as an endogenous immuno-
modulatory, anti-inflammatory and/or anti-microbial substance
(Fitch et al., 2006). By inhibiting IκB degradation, SLPI appears to
have anti-inflammatory functions on leukocytes (Henriksen et al.,
2004; Taggart et al., 2005; Xu et al., 2007). Also, SLPI reduces
inflammatory gene expression and diminishes inflammatory cell
accumulation (Lentsch et al., 1999; Ward and Lentsch, 2002). SLPI is
able to upregulate macrophage production of anti-inflammatory
cytokines (Sano et al., 2000). Also, it prevents release of pro-
inflammatory cytokines by conjunctival epithelial cells (Seto et al.,
2009). However, the in vivo effect of SLPI as an immunosuppressive
agent has not been investigated in detail.
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to tolerate auto-antigens expressed in germ cells. However, inflam-
mation of the testis may occur and is frequently associated with
infertility (Lustig and Tung, 2006). In fact, infection and inflammation
of the male reproductive tract are widely considered important
etiological factors of subfertility or infertility. Fifty percent of
subfertile or infertile patients present different degrees of testicular
lymphocyte infiltrates (Schuppe and Meinhardt, 2005).
EAO is a useful experimental model to study organ-specific
autoimmunity and chronic testicular inflammation. EAO is character-
ized by a testicular interstitial cell infiltrate mainly composed of
dendritic cells (Rival et al., 2007), macrophages (Rival et al., 2008) and
lymphocytes (Jacobo et al., 2009), apoptosis and sloughing of germ cells
from damaged seminiferous tubules resulting in aspermatogenesis and
atrophy of seminiferous tubules (Doncel et al., 1989; Theas et al., 2003).
In contrast with the immunosuppressive microenvironment character-
istic of the normal testis, local secretion of pro-inflammatory cytokines
has a major role in the induction of testicular inflammation (Guazzone
et al., 2009).
It has been shown that is not efficient to administer SLPI
intravenously or intraperitoneally since it is rapidly excreted by the
kidneys (Bergenfeldt et al., 1990; Gast et al., 1990). To avoid this
problem, we developed here a long-acting and controlled release
mechanism for SLPI delivery. Biodegradable polyesters derived from
lactic acid, glycolic acid and ε-caprolactone have been investigated for
use in protein and peptide delivery (Hutchinson and Furr, 1989). The
aim of the present study was to determine whether encapsulated SLPI
might down-regulate testicular inflammation of rats with EAO. In our
work we used poly-ε-caprolactone (PCL) microspheres containing
SLPI as a controlled release system in order to increase its half life.
Methods
Animals
Adult male Sprague–Dawley rats aged 50–60 days were purchased
from Bioterio Central, Facultad de Farmacia y Bioquímica, Universidad
de Buenos Aires (Buenos Aires, Argentina). Animals were kept at 22 °C
with a 14 h light–10 h dark schedule and fed standard food pellets and
water ad libitum. The experiments were performed in accordance
with EC Directive 86/609/ECC and the Use and Care of Experimental
Animals Committee of Facultad de Medicina, Universidad de Buenos
Aires.
Production of recombinant human SLPI
Recombinant human SLPI (SLPI) was cloned and expressed as
described previously (Maffia et al., 2007). Before using SLPI in in vivo
and in vitro experiments, eluted fractions were purified with a
polimixin B column. LPS contamination was b0.1 EU/μg protein as
determined by the Limulus amebocyte lysate assay.
Preparation of microspheres containing SLPI
Microspheres of PCL (poly-ε-caprolactone) (Mw 14,000, Sigma-
Aldrich, St. Louis, MO, USA) containing SLPI or not, were prepared
using a water-in-oil-in-water (A1/O/A2) emulsion based solvent
evaporation technique. Briefly, 400 mg of PCL were dissolved in 10 ml
of dichloromethane (solution O, Anedra, San Fernando, Argentina)
HPLC grade. One ml of a solution containing or not (control
microspheres) 0.8 mg SLPI (A1) and 30 mg of mannitol was added
to the oil solution (O) and mixed with a vortex for 1 min. This first
emulsion (A1/O) was then added with constant stirring to 100 ml of
an aqueous solution of 2% polyvinyl alcohol (A2, Riedel-de Haen, RDH,
Seelze, Germany). The A1/O/A2 emulsion obtained was kept at room
temperature (RT) for 4 h until complete evaporation of dichloro-methane. Microspheres were then collected by centrifugation
(5000 rpm at RT) and washed three times with distilled water.
Finally, the microspheres were lyophilized.
Release kinetics studies
Thirty mg of dried microspheres were suspended in 300 μl of
phosphate buffered saline at pH 7.4 and incubated at 4 °C and 37 °C
for 40 days. Every five days, microspheres were centrifuged and
supernatants recovered in order to evaluate free SLPI concentration.
Afterwards, microspheres were resuspendedwith 300 μl of phosphate
buffer and returned to the selected temperatures. The amount of SLPI
released from microspheres was determined by sandwich ELISA.
SLPI inhibitory activity assay
Inhibitory serine protease activity of SLPI released from micro-
spheres was evaluated by analyzing trypsin enzymatic activity. In
brief, release SLPI (10 μl) was incubated with trypsin (5 μl, 8 mM,
Gibco, Grand Island, NY, USA) for 10 min at RT in a 96-well plate. Then
the colorimetric substrate of trypsin N-succinyl-Ala-Ala-Pro-Phe p-
nitroanilide (12 μg/ml, Sigma-Aldrich St. Louis, MO, USA) was added
to each well. Hydrolysis of the substrate was measured by the
spectrophotometric method at 405 nm in an ELISA plate reader for
50 min.
Induction of EAO
Rats were actively immunized with testicular homogenate (TH)
prepared as previously described (Doncel et al., 1989). Briefly, rat
testes were decapsulated, diluted in an equal volume of saline and
disrupted in an Omni mixer for 30 s. The final concentration was
500 mg/ml wet weight. Rats were injected three times with 200 mg
wet weight of TH/dose per rat at 14 days intervals. Antigen (0.4 ml)
emulsified with 0.4 ml complete Freund's adjuvant (Sigma-Aldrich)
was injected intradermally in footpads and at multiple sites near
popliteal lymph nodes and the neck area. The first two immunizations
were followed by an intravenous injection of 0.5 ml Bordetella
pertussis (Bp) (strain 10536, Instituto Malbrán, Buenos Aires,
Argentina) containing 1010 microorganisms and the third by
intraperitoneal injection of 5×109 microorganisms. Rats were killed
56 days after the first immunization. Blood was collected and sera
stored at −70 °C until use. Popliteal, inguinal, renal and iliac lymph
nodes (LN) and spleen were removed for cell proliferation assay.
Testes were removed, weighed and processed as described below.
Experimental design
A group of rats were injected subcutaneously in the back and sides
with 100 mg of microspheres containing SLPI in 500 μl saline solution
with 1% carboxymethylcellulose and 0.1% Tween 20. Treatment
started 48 h before the first immunization and continued throughout
the experiment at 7 day intervals (treatment 1). For another group of
rats treatment started 7 days after the last immunization (treatment
2). Control rats were immunized with TH and injected with empty
microspheres (vehicle).
Histopathology
Testis histopathology was studied in paraffin-embedded Bouin's-
fixed sections obtained from three different levels and stained with
hematoxylin–eosin. To evaluate the degree of germ cell damage
characteristic of EAO, we used a score described previously (Rival et
al., 2008). Briefly, this score includes (a) percentage of damaged
seminiferous tubules (ST), (b) degree of germ cell sloughing and (c)
testicular/body weight ratio (T/Bw). Therefore, EAO score=V+T+P
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(presenting germ cell sloughing and degeneration); V=0 (0–3%
damaged ST); 1 (3.1–4.9%); 2 (5–15.9%); 3 (16–25.9%); 4 (26–35.9%);
5 (36–55.9%); 6 (56–60.9%); 7 (61–79.9%); 8 (80–95.9%) y 9 (96–
100%). T is an indicator of degree of germ cell sloughing: T=0 when
mild germ cell sloughing is observed and T=0.5 when germ
sloughing is severe (only spermatogonia and Sertoli cells are still
attached to the ST walls). P is a correction factor corresponding to the
T/Bw index: P=0.5 when T/Bw index is less than 2.5×103.Delayed-type hypersensitivity (DTH)
DTH was measured by a footpad swelling test performed at the
end of each experiment. Rats were intradermically challenged in the
left footpad with 2.10 mg of TH supernatant in 50 μl saline. This
fraction was obtained by TH centrifugation (10,000 rpm at 4 °C). The
other footpad was injected with the same volume of saline. Footpad
thickness was measured with a micrometer 48 h after the challenge.
Results of footpad swelling were expressed as mean of at least three
measurements per rat (in mm), calculated as the difference between
the thickness of the HT-injected footpad and the thickness of the
saline injected footpad.SLPI ELISA
A sandwich ELISA for SLPI was used to measure the protein. In
brief, BD Falcon™ 96-well Clear ELISA Plates were coated overnight at
4 °C in coating buffer with 1 μg/ml mouse anti-human SLPI monoclo-
nal antibody (Clone 20409 from R&D Systems, Minneapolis, MN,
USA). Then, the plates were washed and non specific binding sites
were blocked by incubating the wells with PBS-2% BSA in coating
buffer for 30 min at 37 °C. Serially diluted SLPI standard and
samples were then added and incubated overnight at 4 °C. The wells
were then washed and polyclonal goat anti-human SLPI (Hbt, Uden,
Netherlands) was added. After 90 min incubation at 37 °C, the wells
were washed and peroxidase anti-goat IgG (Sigma, St Louis, USA) was
added for 60 min at 37 °C. Then, 50 μl 3,3′,5,5′-tetramethylbenzidine
(Abbott Diagnostics, Buenos Aires, Argentina) substrate solution was
added and incubated for 5–30 min. The reaction was stopped with
50 μl of acidic stop solution and the plate was read at 450 nm.In vitro cell proliferation assay
We used the [3H]-Thymidine incorporation assay to study activity
of SLPI in cell proliferation. Cells from regional lymph nodes (LN,
5×105/well) were cultured in a 96-well plate with Concanavalin A
(Con A 3 μg/well) or TH supernatant (55 μg/ml) in RPMI 1640 (Gibco,
Grand Island, NY, USA), supplemented with heat inactivated 5% FBS
(Gibco), 2 mM L-Glutamine, 0.05 mM 2-mercaptoethanol, 1 mM
sodium pyruvate and 40 μg/ml gentamycin at 37 °C in a 5% CO2
atmosphere. In some experiments, splenocyte proliferation was
assessed in the presence of Con A+SLPI (2.5 μg/well). This concen-
tration was chosen on the basis of previous results obtained with
human peripheral blood mononuclear cells (PBMC).
Proliferation of human PBMC from healthy donors was assayed by
treating cells with IL-2 (8 ng/ml) in the presence of microspheres
(10 mg/well) added above a transwell (TW) bare 0.4-μm polycar-
bonate filter. Cell proliferation was determined on day five post-
treatment with a pulse of 1 μCi/well of [3H]-thymidine (1 μCi/well,
specific activity 5 mCi/mMol; Perkin-Elmer, Boston, MA, USA) for 18
additional hours and harvested on a multi-well cell harvester.
Incorporation of radioactivity was measured in a liquid scintillation
β-counter (1214 Rackbeta LKB Wallac, Perkin Elmer Instruments).Statistical analysis
Comparisons of groups were assessed by the non-parametric
Mann–Whitney test or post hoc Dunnett Multiple Comparisons Test
as indicated in the legend of each figure. P≤0.05 was considered
statistically significant.
Results
Trapped SLPI retained properties of soluble protein
SLPI inhibits human PBMCmitogen-induced proliferation (Guerrieri
et al., in press). Rat SLPI coding sequences are known to be 75%
homologous with human SLPI (Song et al., 1999). However, in order to
assess whether SLPI also inhibits rat lymphocyte proliferation, 5×105
splenocytes were incubated in vitro with Con A (3 μg/well) in the
presence or not of 2.5 μg/well of SLPI for 5 days as described inMethods.
Fig. 1A shows that SLPI decreased splenocyte proliferation induced by
Con A.
In order to determine the relevance of this effect in vivo, we
assessed the immuno-modulatory effect of SLPI in rats with
autoimmune orchitis. Since in vivo SLPI half life is very short
(Bergenfeldt et al., 1990; Gast et al., 1990) we decided to use a
method described in Methods by which SLPI was trapped in order to
increase its half life. We first determined the ability of trapped SLPI to
be released in vitro at 4 or 37 °C over a period of 40 days. Fig. 1B shows
that SLPI was released at both temperatures in the first 24 h followed
by a sustained release rate up to 21 and 30 days for 37° and 4 °C
conditions, respectively. SLPI was detected at a higher concentration
and for a longer period when microspheres were incubated at 4°,
suggesting that higher temperatures may degrade the peptide faster.
We also examined the inhibitory activity of released SLPI from
microspheres by analyzing trypsin inhibitory activity (Fig. 1C). Eleven
day culture supernatant from experiments at 4 °C and 37 °C shown in
Fig. 1B was used to analyze inhibitory activity. As Fig. 1C shows, the
4 °C culture supernatant showed more inhibitory activity on trypsin
than the 37 °C culture supernatant. SLPI biological activity was also
tested on human lymphocyte proliferation. For this, 10 mg of
microspheres with SLPI were placed above a transwell bare
polycarbonate filter (0.4 μm pore size) while human PBMCs treated
with IL-2 were added at the bottom of the transwell for 5 days. On day
6, proliferation was examined. Fig. 1D shows that SLPI release
significantly inhibited lymphocyte proliferation, which suggests that
this poly-ε-caprolactone microsphere system releases a biologically
active protein.
Microspheres containing SLPI reduced the incidence and severity of EAO
Immunoregulatory activity of SLPI was studied in an experimental
in vivo model of autoimmune orchitis. EAO was induced in male
Sprague–Dawley rats as described in Methods. Two experimental
designs were used to analyze activity of SLPI in vivo. In the first one
(treatment 1), microspheres containing SLPI were administered
before the first immunization; in treatment 2, microspheres were
administered after the last immunization and continued until
euthanasia. Histopathology showed that 93% of rats from the control
group (EAO/vehicle treated) developed orchitis. In contrast, a
significant decrease in EAO incidence was observed in rats injected
with SLPI in both treatments (46% and 37.5% for treatments 1 and 2,
respectively). Interestingly, we also found that SLPI significantly
reduced severity of the disease compared to the control group
(p=0.001 versus treatment 1, p=0.035 versus treatment 2)
(Fig. 2A). This finding was confirmed by testicular histopathology
showing that control group (EAO/vehicle treated) presented multi-
focal testicular damage characterized by an interstitial cell infiltrate
composed mainly of monocytes, lymphocytes, macrophages and





































































Fig. 1. (A) Effect of SLPI on cell proliferation. Splenocytes were seeded onto a 24-well plate stimulated with Con A 3 μg/well and incubated in the presence or not of SLPI 2.5 μg/well.
Thymidine incorporation was measured on day 5 by 18 h pulse with [3H]-thymidine 1 μCi/well. Incorporation of radioactivity was measured in a liquid scintillation β-counter.
Results are presented as mean±S.E.M. of triplicate cultures from three experiments. (B) SLPI release kinetics demonstrated sustained release of SLPI at least over a period of 30 days.
Thirty milligrams of dried microspheres were suspended in PBS and tubes were incubated at 4° and 37 °C. Samples were taken at specified time intervals for a total of forty days. The
amount of SLPI released from microspheres was assayed by ELISAs. Results are presented as mean±S.D. of triplicate from one representative experiment (C) SLPI released from
microspheres inhibited trypsin protease activity. Samples from day 11 in 4 °C and 37 °C conditions were incubated with trypsin and the colorimetric substrate N-succinyl-Ala-Ala-
Pro-Phe q-nitroanilide. Absorbance was monitored at 405 nm in a microplate reader. One representative experiment is shown (D) SLPI released frommicrospheres inhibited human
lymphocyte proliferation. Cells were seeded onto 24-well plate stimulated with IL-2 (8 ng/ml) in the presence of SLPI microspheres (10 mg/well) or control microspheres separated
with a 0.4-μm size polycarbonate filter. Thymidine incorporation was measured on day 5 by an 18 h pulse with [3H]-thymidine. Data are presented as the mean±S.E.M. of triplicate
cultures from two experiments. ***pb0.001 by ANOVA post hoc Dunnett Multiple Comparisons Test.
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degrees of germ cell sloughing of the seminiferous tubules (Fig. 2B).
In contrast, most rats treated with SLPI presented little or no infiltrate
and normal seminiferous epitheliumwith both treatments (Fig. 2C for
treatment 2, and data not shown for treatment 1). Body weight of
SLPI-treated rats did not differ from that of untreated normal rats
suggesting that no apparent adverse effects were induced by SLPI
treatments (body weight (g) mean±S.E.M. of 13–16 rats/group:
untreated normal rats, 472.3±11.6; treatment 1, 456.4±19.48 and
treatment 2, 475.0±12.77). Although both treatments prevented
testicular pathology and decreased leukocyte infiltration, the exper-
iments described below were done for the SLPI treatment 2 group in
order to evaluate the immunoregulatory role of SLPI in the effector
phase of the disease.
SLPI reduced cell mediated immunity in vivo and ex vivo
We next investigated effects of SLPI on T cell mediated immunity
by analyzing in vivo DTH response and ex vivo LN lymphocyte
proliferation to testicular antigens. Footpad challenge for DTH was
tested in the treatment 2 group of rats 56 days after immunization.
Fig. 3A shows that footpad swelling was significantly less prominent
in rats treated with SLPI microspheres compared to control group
(EAO/vehicle treated) (pb0.05) (Fig. 3A). LN were also recovered
from SLPI or vehicle-treated rats and lymphocyte proliferation was
assessed ex vivo in response to testicular antigens. Fig. 3B shows that
lymphocyte proliferation of SLPI-treated animals was lower compared
to vehicle-treated animals.Discussion
In this study we demonstrated that SLPI can significantly inhibit
testis damage. This effect of SLPI on EAO implies that SLPI inhibits
multiple pathways either directly as a consequence of its antiprotease
activity or via still undetermined regulatory pathways.
SLPI is secreted at the site of inflammation and presents anti-
inflammatory activity. This anti-inflammatory activity has been
demonstrated in eye and joint inflammation models in which several
anti-inflammatory mechanisms were proposed such as the reduction
of eosinophil and neutrophil recruitment, histamine release, suppres-
sion of NF-κB activation and the production of anti-inflammatory
cytokines such as TGF-β and IL-10 (Murata et al., 2003; Sano et al.,
2000; Sehnert et al., 2004).
The ability of SLPI to reduce autoimmune disease has been
demonstrated in other animal models. Song et al. (1999) reported
the effects of administration of SLPI to autoimmune arthritic rats and
found that the overt tissue destruction and inflammation typically
seen in this model could be suppressed by systemic injections of SLPI.
Also, Mueller et al. (2008) studying the experimental model of myelin
oligodendrocyte protein-induced experimental autoimmune enceph-
alomyelitis (EAE) demonstrated the capacity of SLPI to increase
proliferation of adult neural stem cell and oligodendroglial differen-
tiation suggesting a novel role of SLPI in the promotion of tissue repair.
Furthermore, expression of SLPI in macrophages, activated microglia,
neuronal cells and astrocytes was upregulated more than one
hundredfold during EAE attack. Recently, Wang et al. (2003) reported





















Fig. 2. Administration of SLPI reduced incidence and severity of EAO. (A) EAO score for
rats immunized with TH and adjuvants and injectedwith emptymicrospheres (vehicle)
or microspheres containing SLPI and euthanized 56 days after the first immunization.
Similar EAO mean scores were observed in vehicle group with treatments 1 and 2.
Horizontal lines represent the mean. Each symbol represents a single rat. Values with
different letters superscript differ significantly (pb0.05, Mann–Whitney test). (B and C)
Testicular histopathology from treatment 2 rats. Testis sections from EAO/vehicle (B) or
EAO/SLPI (C) group rats sacrificed 56 days after the first immunization. EAO/vehicle rat
presents a focus of testicular damage characterized by a moderate interstitial
inflammatory cell infiltrate (N) and several seminiferous tubules (*) with different
degrees of germ cell sloughing. In contrast, EAO/SLPI rat presents normal interstitium
and seminiferous tubules. Note the severe tubular atrophy showing decreased diameter
























Fig. 3. (A) DTH is reduced by SLPI treatment. Rats with EAO treated with empty
microspheres (vehicle) or microspheres containing SLPI were tested for DTH to
testicular antigens. Two days before euthanasia (day 54), rats were injected with TH
into left footpad. The right footpad was injected with saline. Footpad swelling was
measured after 48 h and results are expressed as the mean difference between the
thickness of the HT-injected footpad and the thickness of saline-injected footpad±S.E.
M. in each group. *pb0.05 (Mann–Whitney test). n=16 rats/group. (B) SLPI controls'
ex vivo cellular immune response. 5×105 cells obtained from lymph nodes of SLPI or
vehicle-treated rats were cultured in microplates stimulated with 55 μg/ml testicular
antigens (Ag). Thymidine incorporation was measured on day 5 by an 18 h pulse with
[3H]-thymidine 1 μCi/well. Results are presented as mean±S.E.M. from three
independent experiments. **pb0.01 ANOVA post hoc Dunnett Multiple Comparisons
Test. n=16 rats/group.
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expressing SLPI into the cortical tissue resulted in a great reduction in
ischemic lesion suggesting that ischemia-induced expression of SLPI
might play a neuroprotective role in focal stroke.
The clinical application of SLPI is known to be limited due to rapid
enzymatic cleavage by cathepsins and rapid clearance from the blood.The half life of an intravenous injection of SLPI is 120 min (Bergenfeldt
et al., 1990). Approximately 80% of intraperitoneal injected SLPI
(12 mg/kg) generated the maximal plasma concentration of 6 to
10 μg/ml 30 to 120 min after administration. When given intratra-
cheally (8.6 mg/kg), SLPI was absorbed systemically, resulting in
maximal plasma level of about 2 μg/ml 1 to 2 h after application and
disappearing from the lungs with a half-life of 4 to 5 h (Stolk et al.,
1995). Regardless of the route of administration, all studies suggest
that the breakdown of themolecule occurs once it reaches the plasma.
Therefore different formulations have been examined to increase the
half life of this protein. For example, SLPI was encapsulated in 1,2-
Dioleoyl-sn-Glycero-3-[Phospho-L-Serine]: Cholesterol (DOPS: Chol)
liposomes for inhalation. This formulation retained the anti-neutro-
phil elastase in in vitro studies (Gibbons et al., 2009). In our study, the
formulation used was biocompatible both in vitro and in vivo.
Our study did not compare the effect of soluble SLPI versus micro-
encapsulated SLPI. The reason we did not include this group of animals
was based on previous and preliminary results obtained in our
laboratory. They showed that a single administration of encapsulated
SLPI, but not naked SLPI, five days before induction of foot pad
inflammation was able to reduce swelling of mice feet (control 52±
13.4 mm×10−2, encapsulated SLPI: 21±12.5 mm×10−2, naked SLPI:
48±6.2 mm×10−2).However, the administration of naked SLPI was
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administered 5 h before induction of inflammation (SLPI 5 h: 28±
16.1 mm×10−2). These results suggest that administration of
‘naked’ SLPI would be effective in reducing acute but not chronic
inflammation. The lack of effect of naked SLPI on inflammation
caused 5 days later strongly suggests that naked SLPI would not
have been effective in our orchitis model, at least for the second
experimental design (i.e. rat treatment started 7 days after the last
immunization). Therefore, we may speculate that PCL encapsulation
of SLPI improves stability and potentially reduces the level and
frequency of dosing required for therapeutic effect after s.c.
administration.
The microspheres used have good permeability to proteins unlike
other delivery systems such as polylactic acid (PLA) and polyglycolic
acid (PGA) polymers. PCL degrades very slowly and does not generate
an acid environment which can adversely affect the antigenicity of the
peptide (Jameela et al., 1997). In the present study, we also observed
that SLPI encapsulation did not modify anti-proteinase activity,
suggesting that protein integrity was unaffected by encapsulation
methods. However, the properties of temperature incubation modi-
fied the amount and activity of SLPI released: it was higher and more
sustained when microspheres were incubated at 4 °C rather than at
37 °C. Based on these data, microspheres were administered every
7 days. It is important to mention that we were unable to detect blood
SLPI concentration in rats in treatment groups 1 and 2. This could be
due to: i) blood SLPI concentration below the detection limit of ELISA
(1.25 ng/ml), ii) rapid degradation of the peptide; or iii) rapid uptake
by cells and tissues. However, by concentrating the serum samples,
SLPI serum concentration was detected in some animals (data not
shown).
The delivery system used in our study was previously tested for
protein delivery. It has been used for oral immunization, vaccines, mAb,
bovine serumalbumin, nerve growth factor, insulin and steroids (Sinha et
al., 2004). To our knowledge this is the first time that PCL microspheres
were used to deliver a serine proteinase inhibitor, demonstrating that
encapsulation did not modify antiproteinase activity.
The precise mechanism by which SLPI treatment prevents EAO
development is unclear. We may speculate that the mechanisms by
which SLPI reduces EAO may operate in the induction as well as the
effector phase of EAO. In fact, the effectiveness of SLPI in the second
experimental designs and the reduction of DTH showed that the
peptide acts at least in the effector phase. However, since SLPI was
also effective for the first experimental protocol, we cannot discard an
effect on the induction phase as well. We know that SLPI can target
DCs and that it modulates multiple aspects of TLR mediated adaptive
immune responses in mucosal draining LN (Samsom et al., 2007). If
SLPI act on the induction phase of EAO, it may have direct extracellular
interactions with TH. One possibility could be that human recombi-
nant SLPI can bind to TH, thereby decreasing the possibility of immune
cell recognition and interfering with activation of the transcription
factor NF-kB by preventing degradation of inhibitory factor IkBα.
However, the best known activity of SLPI is inhibition of leukocyte
serine proteases. In fact, recombinant human SLPI inhibits murine
serine proteases (Wright et al., 1999) and rat lymphocyte prolifera-
tion (Fig. 1A). We do not know whether the effect of SLPI on rat
lymphocyte proliferation depends on antiprotease activity. However,
preliminary results show that SLPI inhibits human lymphocyte
proliferation an effect that does not depend on SLPI antiprotease
activity (unpublished results). Further studies are needed to clarify
whether reduction of EAO (incidence and severity) depends on SLPI
serine protease activity inhibition.
Conclusion
Altogether, we demonstrate that it is feasible to use microencap-
sulated SLPI to directly reduce autoimmune damage. We also provideinitial preclinical evidence to support use of this serine protease
inhibitor to alleviate orchitis pathology. Based on our study and
others, SLPI may represent a prototype of therapeutic approach for
many autoimmune diseases. The data presented above describe for
the first time that SLPI decreased EAO, even when the peptide is
administered after the induction phase of the disease.
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